Featured Suppliers:

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX - News) today announced that it will webcast its presentations at the

http://finance.yahoo.com/news/Vertex-Pharmaceuticals-bw-2151277650.html?x=0&.v=1

Vertex Pharma reinitiated with "neutral"

www.newratings.com | Oct 21, 2009

NEW YORK, October 21 (newratings.com) - Analysts at Wedbush Morgan reinitiate coverage of Vertex Pharma (ticker: VRTX) with a "neutral" rating. The target price is set to $42. [more]

http://www.newratings.com/en/main/company_headline.m?id=1979336

Vertex Pharmaceuticals Announces Webcast of its Presentation at the Lazard Capital Markets Annual

finance.yahoo.com | Nov 12, 2009

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX - News) today announced that it

http://finance.yahoo.com/news/Vertex-Pharmaceuticals-bw-1712565781.html?x=0&.v=1

News from Zibb.com

Total : 42 View more »

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences -

CAMBRIDGE, Mass., Nov 20, 2009 (BUSINESS WIRE) --

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the Piper Jaffray 21st Annual Health Care Conference on Wednesday, December 2, 2009 at 2:00 p.m. EST and at the 2009 Deutsche Bank Biotech Boston Confab on Tuesday, December 15, 2009 at 9:00 a.m. EST.

The presentations will be webcast live and may be accessed from 'Events & Presentations' on the home page of Vertex's website at www.vrtx.com. A replay of the webcasts will also be available on the Company's website for two weeks following each presentation. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.

About Vertex

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.

Lexiva is a registered trademark of the GlaxoSmithKline group of companies.

Vertex's press releases are available at www.vrtx.com.

(VRTX-WEB)

SOURCE: Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated 
Lora Pike, 617-444-6755 
Associate Director, Investor Relations

Companies: Deutsche Bank AG (DB), Vertex Pharmaceuticals Inc. (VRTX)

Permalink

Vertex Pharmaceuticals (VRTX) Bullish Technical Alert - Trend Up 9.2% - Zibb.com

Nov 16, 2009 (SmarTrend(R) Spotlight via COMTEX) --

Vertex Pharmaceuticals (NASDAQ:VRTX) is trading 0.5% higher (up $0.20 to $40.78) today on volume of 840,222 shares. The stock is trading near its 52-week high of $41.75. We are watching for a close above that level.

Vertex Pharmaceuticals is currently above its 50-day moving average of $35.99 and above its 200-day moving average of $32.76.

SmarTrend is bullish on shares of VRTX and our subscribers received an Uptrend alert on November 02, 2009 at $37.35, which has returned 9.2% to date.

Write to Chip Brian at cbrian@tradethetrend.com

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html

Companies: Vertex Pharmaceuticals Inc. (VRTX)

Permalink

Vertex Pharmaceuticals (VRTX) Downgrade Alert, Watch for 8.4% Technical Uptrend Reversal - Zibb.com

Nov 17, 2009 (SmarTrend(R) Spotlight via COMTEX) --

Vertex Pharmaceuticals (NASDAQ:VRTX) downgraded to Neutral from Buy, $32-39 target, at Merriman. The stock closed yesterday at $40.50 on volume of 2,560,800 shares, above average daily volume of 1,907,525.

Vertex Pharmaceuticals is currently above its 50-day moving average of $35.99 and above its 200-day moving average of $32.76.

SmarTrend is bullish on shares of VRTX and our subscribers received an Uptrend alert on November 02, 2009 at $37.35, which has returned 8.4% to date.

Write to Chip Brian at cbrian@tradethetrend.com

---------------------------------------------------------------------------------------------

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html

Companies: Vertex Pharmaceuticals Inc. (VRTX)

Permalink

Vertex Pharmaceuticals Announces Webcast of its Presentation at the Lazard Capital Markets Annual

CAMBRIDGE, Mass., Nov 12, 2009 (BUSINESS WIRE) --

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009 at 2:40 p.m. EST.

The presentation will be webcast live and may be accessed from 'Events & Presentations' on the home page of Vertex's website at www.vrtx.com. A replay of the webcast will also be available on the Company's website for two weeks following each presentation. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.

About Vertex

Lexiva is a registered trademark of the GlaxoSmithKline group of companies.

Vertex's press releases are available at www.vrtx.com.

(VRTX-WEB)

SOURCE: Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated 
Lora Pike, 617-444-6755 
Associate Director, Investor Relations

Companies: Vertex Pharmaceuticals Inc. (VRTX)

Permalink

Web Sites

Total : 85 View more »

Copyright © 2009 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc. Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use.

http://www.holdrs.com/holdrs/main/index.asp?Action=Headlines&Description=&Image=&symb=VRTX&sid=7853

Drug Discovery & Development Job Search

www.dddmag.com

in the discovery, development, manufacturing and... and finish drug product processes for protein parenteral products at contract manufacturing sites, in...

http://www.dddmag.com/JobSearchResultsXML.aspx?pid=8250162790057827&query=drug+discovery+manufacturing&location=&sort=&radius=25&sitetype=&jobtype=all&sr=&limit=10&fromage=any&start=

PharmaVitae 2002: Vertex Pharmaceuticals (market briefing)

This analysis examines the current position and future outlook for Vertex in the emerging biotechnology sector. It encompasses company strategy, comparative portfolio and pipeline analysis and assessment of financial performance, providing 1, 3 and 6 year sales forecasts for key drugs.

http://www.biz-lib.com/ZDM88017.html

SAS | Customer Success: Vertex Pharmaceuticals

For pharmaceutical and biotechnology companies, the development of a new medicine can take more than a decade – a decade of great expense for the developer and of prolonged anxiety for patients in need of new treatments.

http://www.sas.com/success/vertex.html

Web Sites powered by

Total : 3,280,000 View more »

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences -
Vertex Pharmaceuticals (VRTX) Bullish Technical Alert - Trend Up 9.2% - Zibb.com
Vertex Pharmaceuticals (VRTX) Downgrade Alert, Watch for 8.4% Technical Uptrend Reversal - Zibb.com
Vertex Pharmaceuticals Announces Webcast of its Presentation at the Lazard Capital Markets Annual

Explore Related Topics

Choose a topic :

View all 10 Topics ...

Explore Related Products